Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Latest Semaglutide News and Research

Older adults show interest in deprescribing, study reveals

Older adults show interest in deprescribing, study reveals

Why millions are trying FDA-authorized alternatives to big pharma’s weight loss drugs

Why millions are trying FDA-authorized alternatives to big pharma’s weight loss drugs

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes

Harnessing brain proteins for enhanced diabetes and weight-loss drugs

Harnessing brain proteins for enhanced diabetes and weight-loss drugs

SH2B1 gene defends against obesity via the paraventricular hypothalamus

SH2B1 gene defends against obesity via the paraventricular hypothalamus

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Study reveals potential cognitive benefits of antidiabetic drugs

Study reveals potential cognitive benefits of antidiabetic drugs

How lipoproteins shape your metabolic health

How lipoproteins shape your metabolic health

Tirzepatide outperforms semaglutide in weight loss for overweight and obese adults

Tirzepatide outperforms semaglutide in weight loss for overweight and obese adults

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

Semaglutide linked to increased risk of severe eye condition NAION in new study

Semaglutide linked to increased risk of severe eye condition NAION in new study

GLP-1 drugs found to lower cancer risk in diabetes patients

GLP-1 drugs found to lower cancer risk in diabetes patients

Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetes

Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetes

Natural compound found in olives can lower blood sugar levels and promote weight loss

Natural compound found in olives can lower blood sugar levels and promote weight loss

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.